Clinical studies of the components of the NF-κB signal pathway in breast malignancies

Gershteĭn E.S.; Shcherbakov A.M.; Kushlinskiĭ N.E.

doi:https://doi.org/

Close metadata

Recommended articles:

The possibilities of predicting and reducing the risk of breast cancer in women against the background of the use of assisted reproductive technologies. Russian Bulletin of Obstetrician-Gynecologist. 2025;(1):59-64

Neoadjuvant drug therapy and oncological outcomes in patients with stage I–II breast cancer. P.A. Herzen Journal of Oncology. 2025;(1):5-12

Clinical and psychopathological features of treatment-resistant schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):43-50

The effect of acetylamide synthetic peptide HLDF-6 on cell differentiation in breast cancer. Russian Journal of Archive of Pathology. 2025;(2):5-10

Frequency of MSI, PD-L1 (CPS), HER2 in poorly cohesive gastric carcinomas. Russian Journal of Archive of Pathology. 2025;(2):11-17

Treatment outcomes of stage IIA–IIB breast cancer patients of hormone-positive HER2-negative subtype after neoadjuvant polychemotherapy depending on Ki-67 levels. P.A. Herzen Journal of Oncology. 2025;(2):13-18

Repeated breast reconstruction after previous complications. Pirogov Russian Journal of Surgery. 2025;(6):51-57

Guidelines for assessing the quality of mammographic images. Russian Journal of Preventive Medicine. 2025;(6):21-32

Hematological indicators of the systemic inflammatory response in the prognosis of luminal HER2-negative breast cancer patients undergoing surgery followed by adjuvant therapy. P.A. Herzen Journal of Oncology. 2025;(3):31-38

Hemostasis disorders during neoadjuvant therapy in patients with breast cancer. P.A. Herzen Journal of Oncology. 2025;(3):39-44

Abstract:

Current knowledge of the molecular mechanisms of the occurrence and development of breast cancer (BC) and its susceptibility or resistance to various drugs allows switch from averaged standard therapy regimens to the so-called personalized medicine, i.e. to the use of treatment according to the personality of a patient and the biological characteristics of a tumor. The authors present their data and review current publications on the role of the nuclear transcription factor NF-κB and its related signaling proteins in the formation of the hormonal and drug resistance of BC and on promises for using these indices in clinical practice.

Keywords:

nuclear transcription factor NF-κB

NF-κBp65

NF-κBp50

IκBκ

protein kinase Akt1

steroid hormone receptors

HER2/neu

breast cancer

hormone sensitivity

resistance

Authors:

Gershteĭn E.S.

FGBU "Rossiĭskiĭ onkologicheskiĭ nauchnyĭ tsentr im. N.N. Blokhina" RAMN, Moskva

Shcherbakov A.M.

Nauchno-issledovatel'skiĭ institut onkologii im. N.N. Petrova Minzdrava RF, Sankt-Peterburg

Kushlinskiĭ N.E.

Rossiĭskiĭ onkologicheskiĭ nauchnyĭ tsentr im. N.N. Blokhina RAMN, Moskva

Close metadata

References:

Kushlinskii N.E., Gershtein E.S., Ovchinnikova L.K., Digaeva M.A. Biologicheskie markery opukholei v klinike - dostizheniya, problemy, perspektivy. Molekulyarnaya meditsina 2008; 3: 48-55.
Gershtein E.S., Kushlinskii N.E., Davydov M.I. Retseptory semeistva c-erbB kak misheni molekulyarno-napravlennoi protivoopukholevoi terapii: dostizheniya, problemy, perspektivy. Molekulyarnaya meditsina 2010; 4: 5-10.
Gershtein E.S., Ovchinnikova L.K., Kushlinskii N.E. Rol' yadernogo transkriptsionnogo faktora NF-kappa B v etiologii, patogeneze i klinicheskom techenii raka molochnoi zhelezy. Vopr biol, med i farmatsevt khimii 2009; 5: 10-13.
Baldwin A.S. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 2001; 107 (3): 241-246.
Cao Y., Karin M. NF-kappaB in mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia 2003; 8 (2): 215-223.
Adli M., Baldwin A.S. IKK-i/IKKepsilon controls constitutive, cancer cell-associated NF-kappaB activity via regulation of Ser-536 p65/RelA phosphorylation. J Biol Chem 2006; 281 (37): 26976-26984.
Zhou Y., Eppenberger-Castori S., Eppenberger U., Benz C.C. The NFkappaB pathway and endocrine-resistant breast cancer. Endocr Relat Cancer 2005; 12 (Suppl. 1): S37-46.
Szoltysek K., Pietranek K., Kalinowska-Herok M. et al. TNFalpha-induced activation of NFkappaB protects against UV-induced apoptosis specifically in p53-proficient cells. Acta Biochim Pol 2008; 55 (4): 741-748.
Bhat-Nakshatri P., Sweeney C.J., Nakshatri H. Identification of signal transduction pathways involved in constitutive NF-kappaB activation in breast cancer cells. Oncogene 2002; 21 (13): 2066-2078.
Dan H.C., Cooper M.J., Cogswell P.C. et al. Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK. Genes Dev 2008; 22 (11): 1490-1500.
Sliva D., Rizzo M.T., English D. Phosphatidylinositol 3-kinase and NF-kappaB regulate motility of invasive MDA-MB-231 human breast cancer cells by the secretion of urokinase-type plasminogen activator. J Biol Chem 2002; 277 (5): 3150-3157.
Biswas D.K., Iglehart J.D. Linkage between EGFR family receptors and nuclear factor kappaB (NF-kappaB) signaling in breast cancer. J Cell Physiol 2006; 209 (3): 645-652.
Pratt M.A., Bishop T.E., White D. et al. Estrogen withdrawal-induced NF-kappaB activity and bcl-3 expression in breast cancer cells: roles in growth and hormone independence. Mol Cell Biol 2003; 23 (19): 6887-6900.
deGraffenried L.A., Chandrasekar B., Friedrichs W.E. et al. NF-kappa B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen. Ann Oncol 2004; 15 (6): 885-890.
Zhou Y., Yau C., Gray J.W. et al. Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer 2007; 7: 59.
Weldon C.B., Burow M.E., Rolfe K.W., Clayton J.L., Jaffe B.M., Beckman B.S. NF-kappa B-mediated chemoresistance in breast cancer cells. Surgery 2001; 130 (2): 143-150.
Hernandez-Vargas H., Rodriguez-Pinilla S.M., Julian-Tendero M., Sanchez-Rovira P., Cuevas C., Anton A., Rios M.J., Palacios J., Moreno-Bueno G. Gene expression profiling of breast cancer cells in response to gemcitabine: NF-kappaB pathway activation as a potential mechanism of resistance. Breast Cancer Res Treat 2007; 102 (2): 157-172.
Scherbakov A.M., Lobanova Y.S., Andreeva O.E., Shatskaya V.A., Krasil'nikov M.A. Oestrogen treatment enhances the sensitivity of hormone-resistant breast cancer cells to doxorubicin. Biosci Rep 2010; 31 (2): 137-143.
Ahmed K.M., Cao N., Li J.J. HER-2 and NF-kappaB as the targets for therapy-resistant breast cancer. Anticancer Res 2006; 26 (6B): 4235-4243.
Russo S.M., Tepper J.E., Baldwin A.S. Jr. et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys 2001; 50 (1): 183-193.
Park B.K., Zhang H., Zeng Q. et al. NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat Med 2007; 13 (1): 62-69.
Jones M.D., Liu J.C., Barthel T.K. et al. A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes. Clin Cancer Res 2010; 16 (20): 4978-4989.
Xu J., Wu H.F., Ang E.S. et al. NF-kappaB modulators in osteolytic bone diseases. Cytokine Growth Factor Rev 2009; 20 (1): 7-17.
Mayo M.W., Baldwin A.S. The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta 2000; 1470 (2): M55-62.
Wu J.T., Kral J.G. The NF-kappaB/IkappaB signaling system: a molecular target in breast cancer therapy. J Surg Res 2005; 123 (1): 158-169.
Orlowski R.Z., Baldwin A.S., Jr. NF-kappaB as a therapeutic target in cancer. Trends Mol Med 2002; 8 (8): 385-389.
Rahman K.M., Ali S., Aboukameel A., Sarkar S.H., Wang Z., Philip P.A., Sakr W.A., Raz A. Inactivation of NF-kappaB by 3,3'-diindolylmethane contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells. Mol Cancer Ther 2007; 6 (10): 2757-2765.
Kim H.J., Hawke N., Baldwin A.S. NF-kappaB and IKK as therapeutic targets in cancer. Cell Death Differ 2006; 13 (5): 738-747.
Chen F. Endogenous inhibitors of nuclear factor-kappaB, an opportunity for cancer control. Cancer Res 2004; 64 (22): 8135-8138.
Cardoso F., Ross J.S., Picart M.J. et al. Targeting the ubiquitin-proteasome pathway in breast cancer. Clin Breast Cancer 2004; 5 (2): 148-157.
Pajak B., Gajkowska B., Orzechowski A. Molecular basis of parthenolide-dependent proapoptotic activity in cancer cells. Folia Histochem Cytobiol 2008; 46 (2): 129-135.
Jenkins C., Hewamana S., Gilkes A. et al. Nuclear factor-kappaB as a potential therapeutic target for the novel ccute myeloid leukaemia. Br J Haematol 2008; 143 (5): 661-671.
Zhou Y., Eppenberger-Castori S., Marx C. et al. Activation of nuclear factor-kappaB (NFkappaB) identifies a high-risk subset of hormone-dependent breast cancers. Int J Biochem Cell Biol 2005; 37 (5): 1130-1144.
Gershtein E.S., Kushlinskii N.E., Shcherbakov A.M., Platova A.M., Chemeris G.Yu., Oshkina E.V., Tuleuova A.A., Letyagin V.P. Sravnitel'nyi immunofermentnyi analiz ekspressii i aktivnosti yader-nogo transkriptsionnogo faktora NF-kB, ego ingibitora IkBa i vyshelezhashchei effektornoi proteinkinazy Akt1 v opukholyakh bol'nykh rakom molochnoi zhelezy. Vopr biol, med i farmatsevt khimii 2011; (8): 56-60.
Gershtein E.S., Shcherbakov A.M., Platova A.M., Chemeris G.Yu., Letyagin V.P., Kushlinskii N.E. Ekspressiya i DNK-svyazyvayushchaya aktivnost' yadernogo transkriptsionnogo faktora NF-kB v opukholyakh bol'nykh rakom molochnoi zhelezy. Byul eksp biol med 2010; 150 (7): 80-84.
Gershtein E.S., Kushlinskii N.E. Nekotorye komponenty NF-kB signal'nogo puti v opukholyakh bol'nykh rakom molochnoi zhelezy: rol' v prognoze gormonal'noi i lekarstvennoi rezistentnosti. Molekulyarnaya meditsina 2011; (4): 12-19.
Gershtein E.S., Shcherbakov A.M., Platova A.M. i dr. Ekspressiya i aktivnost' yadernogo transkriptsionnogo faktora NF-κB, ego ingibitora IκBκ i proteinkinazy Akt1 v opukholyakh bol'nykh rakom molochnoi zhelezy. Al'manakh klinicheskoi meditsiny 2010; 22: 55-61.
Gershtein E.S., Shatskaya V.A., Ermilova V.D. et al. Phospatidylinositol 3-kinase expression in human breast cancer. Clin Chim Acta 1999; 287 (1-2): 59-67.
Gershtein E.S., Scherbakov A.M., Shatskaya V.A. et al. Phosphatidylinositol 3-kinase/AKT signalling pathway components in human breast cancer: clinicopathological correlations. Anticancer Res 2007; 27 (4A): 1777-1782.
Gershtein E.S., Scherbakov A.M., Anurova O.A. et al. Phosphorylated Akt1 in human breast cancer measured by direct sandwich enzyme-linked immunosorbent assay: Correlation with clinicopathological features and tumor VEGF-signaling system component levels. Int J Biol Markers 2006; 21 (1): 12-19.
Shcherbakov A.M., Gershtein E.S., Anurova O.A., Kushlinskii N.E. Aktivirovannaya proteinkinaza V pri rake molochnoi zhelezy. Byul eksper biol med 2005; 139 (5): 570-572.
Liu C., Zhou S., Ke C.S. et al. Activation and prognostic significance of AKT, NF-kappaB and STAT3 in breast cancer with lymph node metastasis and estrogen receptor expression. Ai Zheng 2007; 26 (9): 929-936.
Van Laere S.J., van der Auwera I., van den Eynden G.G. et al. NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation. Br J Cancer 2007; 97 (5): 659-669.